Plain-English translation of NCT07078591 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether —a newer leukemia medication—works better when combined with immune cells donated by a family member to fight acute myeloid leukemia (AML). Researchers want to see if adding donor cells to the medication can help more patients survive longer and have better outcomes. The study will enroll 50 newly diagnosed adult patients at a hospital in Beijing.
Acute myeloid leukemia is a serious blood cancer, and while existing treatments help some patients, doctors are looking for ways to improve survival rates. This trial combines the medication with donor immune cells in a newer approach called a 'microtransplant' to see if it can be more effective than current standard treatments.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive chemotherapy combined with as an 'induction' phase to try to put your leukemia into remission, followed by a 'consolidation' phase with additional chemotherapy, , and donor cell infusions spread over several months. The exact schedule depends on your age and genetics of your leukemia. You will have regular blood tests, imaging, and clinic visits to monitor your response and side effects throughout the treatment.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China